Version May 2024
Nasal congestion: Intranasal: Instill 2 to 4 drops or 3 to 4 sprays of 0.1% solution into each nostril every 3 to 4 hours as needed, no more frequently than every 3 hours.
Duration: Generally, limit to 3 to 5 days of consecutive use due to risk of rhinitis medicamentosa (Ref). In patients with persistent symptoms despite use of first-line therapies, some guidelines suggest intranasal decongestants may be offered in combination with an intranasal corticosteroid for up to 4 weeks with low risk of rhinitis medicamentosa (Ref).
Refer to adult dosing.
Nasal congestion: Intranasal:
Children 2-6 years: Instill 2-3 drops of 0.05% solution into each nostril every 4-6 hours as needed, no more frequently than every 3 hours
Children >6 years: Refer to adult dosing.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
>10%: Respiratory: Sneezing, stinging sensation of the nose
1% to 10%:
Cardiovascular: Hypertension, palpitations, tachycardia
Central nervous system: Headache
Neuromuscular & skeletal: Tremor
Ophthalmic: Blurred vision
Hypersensitivity to tetrahydrozoline or any component of the formulation. The 0.5% solution is contraindicated in children <2 years of age. The 0.1% solution is contraindicated in children <6 years of age.
Concerns related to adverse effects:
• Somnolence: Profound sedation may occur in children following overdose. This may be accompanied by diaphoresis, hypotension, and/or shock. Do not exceed recommended dosages.
Disease-related concerns:
• Cardiovascular disease: Use with caution in patients with cardiovascular disease, including hypertension and coronary artery disease.
• Endocrine disorders: Use with caution in patients with endocrine disorders, including diabetes and hyperthyroidism.
Other warnings/precautions:
• Appropriate use: For intranasal use only.
• Accidental ingestion: Accidental ingestion by children of over-the-counter (OTC) imidazoline-derivative eye drops and nasal sprays may result in serious harm. Serious adverse reactions (eg, coma, bradycardia, respiratory depression, sedation) requiring hospitalization have been reported in children ≤5 years of age who had ingested even small amounts (eg, 1-2 mL). Contact a poison control center and seek emergency medical care immediately for accidental ingestion (FDA Drug Safety Communication, 2012).
No
Solution (Tyzine Nasal)
0.05% (15 mL): $91.78
Disclaimer: The pricing data provide a representative AWP and/or AAWP price from a single manufacturer of the brand and/or generic product, respectively. The pricing data should be used for benchmarking purposes only, and as such should not be used to set or adjudicate any prices for reimbursement or purchasing functions. Pricing data is updated monthly.
Symptomatic relief of nasal congestion
Accidental ingestion: Serious adverse reactions (eg, coma, bradycardia, respiratory depression, sedation) requiring hospitalization have been reported in children ≤5 years of age who have accidentally ingested even small amounts (eg, 1-2 mL) of imidazoline-derivative (ie, tetrahydrozoline, oxymetazoline, or naphazoline) eye drops or nasal sprays. Store these products out of reach of children at all times. Contact poison control or seek medical attention if accidental ingestion occurs.
None known.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.
Esketamine: Decongestants (Nasally Administered) may diminish the therapeutic effect of Esketamine. Management: Patients who require a nasal decongestant on an esketamine dosing day should administer the nasal decongestant at least 1 hour before esketamine. Risk D: Consider therapy modification
FentaNYL: Decongestants may decrease the serum concentration of FentaNYL. Risk C: Monitor therapy
Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Tetrahydrozoline (Nasal). Risk X: Avoid combination
Zavegepant: Decongestants (Nasally Administered) may decrease the serum concentration of Zavegepant. Management: Avoid the concurrent administration of intranasal decongestants with zavegepant. If combined use is unavoidable, intranasal decongestants should be administered at least 1 hour after zavegepant administration. Risk D: Consider therapy modification
Animal reproduction studies have not been conducted.
Blood pressure, heart rate, symptom response
Stimulates alpha-adrenergic receptors in the arterioles of the nasal mucosa to produce vasoconstriction
Onset of action: Decongestant: 4-8 hours
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
